What Procto-Synalar N Treats: Main Uses and Benefits

Procto-Synalar N is primarily used in situations involving certain distressing symptoms, offering symptomatic assistance against pronounced localized pain, severe burning sensations, and intense anal itching (pruritus). The therapeutic benefit of easing this acute sensory distress involves the role of topical local anesthetics in managing discomfort associated with anorectal disorders. By easing these challenging manifestations, the medication provides support that generally contributes to improved comfort during periods of heightened symptoms and assists with managing symptoms that interfere with routine activities.

The medication is commonly applied across domains where additional symptomatic support is needed to address the heightened inflammatory response and physical symptoms, including localized tissue swelling and redness. It is relevant in conditions characterized by periods of heightened symptoms, such as symptomatic hemorrhoids (both internal and external), anal inflammation, and perianal dermatitis.

The product is commonly used when symptoms intensify and supportive relief is needed, helping to address symptom clusters that interfere with daily comfort. It provides short-term symptomatic assistance relevant to easing the impact of acute or disruptive episodes.

“The medication provides support that helps ease the overall symptom burden during difficult episodes.”

Quick Fact: Relief for Acute Anorectal Symptoms
Primary Symptom Domains	Pain, Burning, Swelling, Pruritus
Typical Clinical Context	Acute symptomatic flare-ups, Conservative management
Patient Benefit	Supports comfort, Eases overall symptom load

Who Can and Cannot Use Procto-Synalar N?

The population eligibility for Procto-Synalar N is strictly defined by regulatory documents, which establish clear contraindications and limitations on use.

---

Contraindicated Populations (Must NOT Use)	Restricted Use / Caution Required
Known hypersensitivity to Fluocinolone acetonide, Lidocaine, or excipients.	Infants and toddlers (not to be treated; lack of data).
Active local infections (tubercular, syphilitic, bacterial, viral, or fungal).	Children under 12 (use not established; increased systemic risk).
Severe systemic conditions (e.g., Severe Renal Disease, Psychosis).	Patients with Severe Hepatic Impairment or metabolic disorders (e.g., Diabetes, Cushing's syndrome).

---

Pregnancy and Lactation Eligibility Status

Use during pregnancy and breastfeeding is generally not recommended unless the potential benefit justifies the risk. The medication must not be applied in large quantities or for long periods, especially in the first trimester. Administration should be limited to the minimum necessary amount and duration.

Connection to the overall eligibility profile

Regulatory documents define who can and cannot use the medicine by establishing clear absolute prohibitions for populations with specific diseases or allergies. Eligibility is further structured by strict age limitations and requirements for cautionary use in patients with compromised organ function or metabolic conditions, ensuring use is confined to label-defined criteria.

Interactions with other medicines and products

The official regulatory profile for Procto-Synalar N is structured around the potential systemic exposure and metabolic pathway of its active local anesthetic component, Lidocaine hydrochloride. The documented interaction patterns primarily describe how certain co-administered medicines may alter lidocaine's plasma concentrations or contribute to its pharmacologic effect.

Pharmacokinetic and Pharmacodynamic Interactions

Category	Interacting Agents	Official Interaction Outcome
Metabolic Inhibition	CYP1A2 and CYP3A4 Inhibitors (e.g., Fluvoxamine, Cimetidine)	May increase lidocaine plasma levels by reducing clearance.
Pharmacodynamic Effects	Other Antiarrhythmic Drugs (e.g., Amiodarone)	Potential for additive or antagonistic cardiac effects; toxic effects may be additive.
Exposure Modification	Beta-adrenergic Blockers (e.g., Propranolol)	May increase lidocaine plasma levels by decreasing hepatic blood flow.
Additive Toxicity	Other Local Anesthetic Agents	Toxic effects are additive.

No mandatory timing separation rules are explicitly documented in the official prescribing information for this rectal combination product. Regulatory documents note that patients with severe hepatic or renal dysfunction are at greater risk of developing toxic lidocaine concentrations due to compromised clearance. No specific food, alcohol, or herbal product interactions are mandated as restrictions.

Voltage-Gated Sodium Channel Inhibition

This mechanism is mediated by lidocaine, which targets peripheral sensory nerve cells by reversibly binding to and blocking voltage-gated sodium channels ( Nav). This inhibition prevents the transient influx of Na^+ ions required for nerve cell depolarization and halts the propagation of action potentials along sensory fibers.

Glucocorticoid Receptor Activation and Pathway Modulation

The corticosteroid, fluocinolone acetonide, works by activating intracellular glucocorticoid receptors. The drug-receptor complex modulates gene transcription, resulting in the increased synthesis of proteins that inhibit key enzymes like Phospholipase A2 ( PLA2). Blocking PLA2 prevents the upstream synthesis of eicosanoid mediators, including prostaglandins and leukotrienes.

Integrated Vascular Response and Permeability Control

The mechanism also promotes vasoconstriction (narrowing of vessels). This response lowers regional blood flow and limits capillary permeability, which results in decreased localized edema and erythema.

Instructions for Use

The administration of Procto-Synalar N, a combination product containing fluocinolone acetonide and lidocaine hydrochloride, follows a localized, short-term protocol.

Administration Scope

Instruction	Detail
Route of Administration	Rectal and Topical (for external application to the perianal area).
Dosing Schedule	Apply a thin film of the cream to the affected area.
Frequency and Timing	Apply the cream two to four times daily; the application frequency should be limited to the amount necessary to manage acute symptoms.
Preparation requirements	The targeted area should be cleaned and gently dried immediately prior to application.
Age-group administration rules	Use and dose in children must be determined by a physician, as the administration of topical steroids requires professional guidance.
Special procedural conditions	The treated area must not be bandaged or covered with an occlusive dressing unless specifically instructed by a healthcare provider. For infants, tight-fitting diapers or plastic pants should be avoided as they may constitute an occlusive dressing.

---

Instruction Classifications

The usage protocol establishes the medicine as a strictly topical (rectal/external) administration with a multiple times per day frequency pattern. This protocol is applied in the context of short-term symptomatic management.

Resulting Procedural Structure

Application is structured by the following sequence:

• The targeted area is first prepared by cleansing and drying.
• A thin film of the cream is then applied directly to the affected external area or inserted rectally.
• The application is repeated according to the prescribed divided-use frequency.
• The area is left uncovered to avoid occlusion, unless advised otherwise.

This sequence defines the method for delivering the product to the affected area, ensuring administration follows the described parameters.

Research Evidence / Overview of Studies for Procto-Synalar N

This overview describes the clinical research landscape for the active components—Fluocinolone acetonide (corticosteroid) and Lidocaine hydrochloride (local anesthetic)—in topical anorectal preparations, focusing on the available evidence and where limitations exist.

---

Evidence for Use in Symptomatic Hemorrhoidal Disease

Research has examined the combination of a topical corticosteroid and a local anesthetic was studied for the context of acute flare-ups in symptomatic hemorrhoidal disease. This research primarily involved short-term Randomized Controlled Trials (RCTs) and observational settings in adults with Grade I and Grade II hemorrhoids. Studies monitored patient-reported outcomes describing perceived discomfort such as pain intensity, burning, itching (pruritus), and localized swelling.

The findings describe patterns observed in the studies over the short treatment duration, particularly patterns related to measured changes in pain and irritation. The evidence quality varies across studies, and there is a limited number of large-scale RCTs that specifically evaluate this exact formulation against an inactive substance.

---

Evidence for Use in Perianal Inflammation and Dermatitis

Research has examined the use of this combination for conditions characterized by fluctuating or episodic manifestations in the skin. The evidence largely relies on the known profile of the corticosteroid component from clinical observation and comparative studies. Research examined outcomes linked to inflammatory or irritative states, such as the degree of redness and tissue swelling, and studies monitored changes in patient-reported itching intensity.

A key limitation is that comparative evidence is lacking for the full fixed-dose combination, and the findings largely stem from the established action of the corticosteroid class. Limited information is available regarding the specific role of the local anesthetic on overall dermatological healing outcomes.

---

What is Still Uncertain About the Research Landscape

The research exploring this combination primarily focuses on acute or disruptive episodes, meaning the follow-up durations were limited and generally do not extend far beyond the typical treatment period. Consequently, long-term effects are not fully established. Research does not determine whether an individual will respond similarly; study results reflect the specific conditions under which they were conducted.

Key Studies & References

1. A Systematic Review of the Topical Drugs for Post Hemorrhoidectomy Pain - Science Alert

Common questions about Procto-Synalar N (FAQ)

---

Q: What is the difference between Procto-Synalar N and regular hemorrhoid cream?

Official product information describes this medicine as a combination product. It contains two distinct active ingredients: a corticosteroid (fluocinolone acetonide) to help with inflammation, and a local anesthetic (lidocaine hydrochloride) intended for immediate pain relief. This dual-action approach is what distinguishes it from typical single-ingredient treatments.

---

Q: Why is Procto-Synalar N sometimes prescribed for anal fissures?

Official indications describe the medication's use for treating inflammation, itching, and pain associated with a range of conditions in the rectoanal region. This includes conditions like proctitis, perianal eczema, and hemorrhoids. The application is typically intended to help manage the localized symptoms of pain and inflammation in the affected area.

---

Q: What are the most common side effects listed for Procto-Synalar N?

According to official documentation, the most commonly documented adverse reactions are localized reactions at the application site. Examples include burning, itching, and irritation. Other potential effects have a frequency that is not known or are described as associated with prolonged use.

---

Q: Does Procto-Synalar N cause itching or burning when first applied?

Localized burning, itching, and irritation are listed as known adverse reactions in regulatory sources. Some official patient information indicates that this type of irritation can occur when the medication is first applied. This is documented as a possible effect that some reports indicate may reduce over time.

---

Q: What is the risk of an allergic reaction to Procto-Synalar N?

Hypersensitivity (allergic reaction) to any of the product's components is listed as a contraindication (a reason not to use the drug) in regulatory documents. Local hypersensitivity reactions are also documented as possible adverse reactions, though their frequency is not known.

---

Q: Does Procto-Synalar N need to be kept in the refrigerator?

Official storage instructions require that the product be kept at room temperature, typically defined as between 15 C and 25 C (59 F and 77 F). The product information also explicitly states that the medication should not be frozen.

---

Q: What research evidence supports the use of Procto-Synalar N for its main indications?

Studies have examined the combination of a corticosteroid and local anesthetic for conditions like symptomatic hemorrhoidal disease and perianal inflammation. Researchers monitored patient-reported outcomes such as changes in pain, itching, and swelling. Regulatory overviews state that the evidence quality varies across studies and generally focuses on short-term results.

---

Q: Are there any studies comparing the components of Procto-Synalar N to similar combination drugs?

The research overviews available in official documents note that comparative evidence is lacking for the full fixed-dose combination. Therefore, specific head-to-head study findings against similar combination drugs are not broadly available in the regulatory summaries.

---

Q: Do any official documents describe the use of Procto-Synalar N for eczema near the affected area?

Yes, official indications for this medication include the symptomatic treatment of conditions such as perianal eczema. The product is indicated for inflammatory skin diseases that are responsive to topical corticosteroids.

---

Q: Why does Procto-Synalar N include both a corticosteroid and an antimicrobial agent?

The formulation is a dual-action product that merges an anti-inflammatory agent (fluocinolone acetonide) with an immediate analgesic agent (lidocaine hydrochloride). The inclusion of 'N' often signifies Neomycin, an antibiotic, which is added to address the potential presence of certain bacterial organisms in the inflamed area.

---

Q: What types of food or drinks should be avoided while using Procto-Synalar N?

According to the official prescribing information, there are no specific food, alcohol, or herbal product interactions that are mandated as restrictions for this rectal combination product.

---

Q: What is the approved duration of treatment for Procto-Synalar N according to regulators?

Official guidance emphasizes that this medicine is intended for short-term symptomatic management. The typical duration of treatment often depends on the symptoms, but is generally advised to not exceed 2–3 weeks. Regulatory documents describe an increased risk of systemic side effects if used for a prolonged period.

---

Q: Are there different strengths or formulations of Procto-Synalar N available?

The product is typically presented in multiple dosage forms, which may include a Rectal Cream or Ointment and Suppositories. The availability of different strengths may vary depending on the specific product line and region.

---

Q: What should I do if Procto-Synalar N accidentally gets into my eyes?

Official patient information indicates that contact with the eyes should be avoided. If accidental contact occurs, the affected area should be rinsed off immediately with water.

---

Q: Is it normal to experience a headache after applying this medication?

While less common, headache is listed in some regulatory documents as a potential side effect for products containing topical fluocinolone. This effect is generally classified as having an unknown or less frequent incidence.

---

Q: What does official guidance say about using Procto-Synalar N if you have a fungal infection?

Official documents state that the medication is contraindicated (not recommended for use) in areas affected by active local infections. This includes fungal infections, as well as viral, bacterial, and tubercular diseases.

---

Q: Is there a maximum amount of Procto-Synalar N that can be used safely?

Official instructions specify that patients should apply only a thin film of the cream to the affected area. Regulatory documents caution that using large amounts or applying over a large surface area increases the risk of systemic effects from the corticosteroid component.

---

Q: Can Procto-Synalar N be used for pain relief?

Yes, the overall general purpose of this combination product is to provide simultaneous, symptomatic relief from localized discomfort. Its dual composition includes lidocaine hydrochloride, a local anesthetic, which specifically contributes to immediate relief from intense pain, burning, and itching.

---

Q: What are the key differences between the ointment and cream forms of the drug, if both exist?

Regulatory descriptions indicate that the choice of formulation is often related to the condition being treated. The ointment form is generally described as being more suitable when an emollient or moisturizing effect is desired, while the cream form is used for general application.

---

Q: Is Procto-Synalar N gluten-free or suitable for people with specific allergies?

The medication is contraindicated for patients with a known hypersensitivity to the active ingredients or any of the non-active components (excipients) in the formulation. This means patients with known allergies should review the excipient list in the official patient information.

Storage and Disposal Requirements

Official Storage Conditions

Procto-Synalar N must be stored under controlled environmental conditions to maintain its labeled stability. The product should be kept at room temperature, generally between 20 C and 25 C (68 F and 77 F). Storage areas must be protected from moisture and direct light, and it is strictly required to not freeze the medication. It is mandatory to store the medicine in the original container, ensuring it is tightly closed when not in use.

Child Safety and Disposal

For safety, the medication must be stored out of the sight and reach of children, and any safety caps should be locked. When disposing of unused or expired Procto-Synalar N, it must not be thrown away in household waste or wastewater. Regulatory instructions require consulting a pharmacist or healthcare professional for guidance on proper pharmaceutical waste disposal.